Abbott launches pivotal trial of Cephea mitral valve replacement device

• Abbott initiated the CROWN-MV pivotal trial to evaluate the safety and effectiveness of its investigational Cephea mitral valve replacement system.
• The study will enroll up to 585 patients in the U.S., Canada and Europe.
• Eligible patients have moderate-to-severe or severe mitral regurgitation or calcium-related valve dysfunction and cannot undergo surgery or transcatheter repair.
• Cephea delivers a replacement tissue valve through a catheter inserted into a leg vein, offering a minimally invasive approach.
• Researchers will present 30-day early feasibility outcomes for Cephea's third-generation delivery system at TCT 2026 on Nov. 1.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: CG81405) on October 29, 2026, and is solely responsible for the information contained therein.